Clinical Study
Oxidant-Antioxidant Balance during On-Pump Coronary Artery Bypass Grafting
Table 1
Demographic data of groups.
| | | Whole patients () | Group 1 () | Group 2 () | value* |
| | Age, year | 62.87 ± 10.310 | 63.64 ± 8.582 | 62.17 ± 12.021 | 0.741 | | Male, (%) | 17 (73.9%) | 8 (72.7%) | 9 (75.0%) | 0.901 | | BSA (m2) | 1.838 ± 0.175 | 1.848 ± 0.193 | 1.828 ± 0.165 | 0.793 | | Urea (mg/dL) | 38.13 ± 10.385 | 35.91 ± 13.217 | 40.17 ± 6.887 | 0.338 | | Creatinine (mg/dL) | 0.939 ± 0.282 | 0.918 ± 0.299 | 0.958 ± 0.278 | 0.742 | | ALT (U/L) | 28.57 ± 18.571 | 22.64 ± 10.856 | 34.00 ± 22.700 |
0.147 | | AST (U/L) | 32.96 ± 18.826 | 35.09 ± 22.170 | 31.00 ± 15.915 | 0.614 | | ACE inhibitors, (%) | 11 (47.8%) | 4 (36.4%) | 7 (58.3%) | 0.292 | | Calcium antagonists, (%) | 1 (4.3%) | 0 (0%) | 1 (8.3%) | 0.328 | | Beta blockers, (%) | 4 (17.4%) | 2 (18.2%) | 2 (16.7%) | 0.924 | | Nitrates, (%) | 5 (21.7%) | 2 (18.2%) | 3 (25.0%) | 0.692 | | HT, (%) | 17 (73.9%) | 7 (63.6%) | 10 (83.3%) | 0.283 | | DM, (%) | 5 (21.7%) | 2 (18.2%) | 3 (25.0%) | 0.692 | | COPD, (%) | 3 (13.0%) | 2 (18.2%) | 1 (8.3%) | 0.484 | | PAD, (%) | 2 (8.7%) | 1 (9.1%) | 1 (8.3%) | 0.949 | | CVD, (%) | 1 (4.3%) | 0 (0%) | 1 (8.3%) | 0.328 | | Smoking, (%) | 7 (30.4%) | 2 (18.2%) | 5 (41.7%) | 0.221 | |
Alcohol, (%) | 1 (4.5%) | 1 (9.1%) | 0 (0%) | 0.306 | | CCS class | 2.26 ± 0.449 | 2.36 ± 0.505 | 2.17 ± 0.389 | 0.304 | | LVEF | 53.48 ± 9.224 | 52.27 ± 8.475 | 54.58 ± 10.104 | 0.561 | | LMCAD | 1 (4.3%) | 0 (0%) | 1 (8.3%) | 0.328 |
|
|
*Comparison of group 1 and group 2.
ACE: angiotensin converting enzyme, ALT: alanine aminotransferase, AST: aspartate aminotransferase, BSA: body surface area, CCS: Canadian Cardiovascular Society, COPD: chronic obstructive pulmonary disease, CVD: cerebrovascular disease, DM: diabetes mellitus, HT: hypertension, LMCAD: left main coronary artery disease, LVEF: left ventricular ejection fraction, and PAD: peripheral arterial disease.
|
